IP Ownership Risk Grows In Booming Cancer Drug Market
The antibody-drug conjugate, or ADC, space is experiencing an unprecedented surge in dealmaking, establishing itself as one of the most dynamic and high-value domains within biopharma....To view the full article, register now.
Already a subscriber? Click here to view full article